Back to top

vaccines: Archive

Zacks Equity Research

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.

NVOPositive Net Change SRPTPositive Net Change EBSPositive Net Change CTMXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

NVOPositive Net Change MRKPositive Net Change MRNAPositive Net Change CTMXPositive Net Change

Derek Lewis

Bear of the Day: Pfizer (PFE)

Negative earnings estimate revisions from analysts and weakening sales post-pandemic paint a challenging picture for the company's shares in the near term.

PFEPositive Net Change

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

MRKPositive Net Change MRNAPositive Net Change SRPTPositive Net Change CTMXPositive Net Change